Approximately 30% and 8% of ALK-negative ALCL patients have DUSP22 and TP63 rearrangement, respectively, and ALCL patients with TP63 rearrangement have a worse prognosis, while patients with DUSP22 rearrangement generally have an intermediate or good prognosis2,5,6. This evidence concerns the gene ALK and anaplastic large cell lymphoma.